Cargando…

A targeted therapy for melanoma by graphene oxide composite with microRNA carrier

BACKGROUND: Nowadays, the combination of microRNA (miR) is attracting increased attention in clinical cancer trials. However, the clinical use of miR is highly limited because of certain properties such as instability, low-specificity distribution, and metabolic toxicity. METHODS: In order to improv...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Can, Xie, Huiqing, Yu, Jingang, Chen, Xiaoqing, Tang, Shijie, Sun, Lichun, Chen, Xiang, Peng, Defei, Zhang, Xiangyan, Zhou, Jianda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6157538/
https://www.ncbi.nlm.nih.gov/pubmed/30275686
http://dx.doi.org/10.2147/DDDT.S160088
_version_ 1783358285787693056
author Liu, Can
Xie, Huiqing
Yu, Jingang
Chen, Xiaoqing
Tang, Shijie
Sun, Lichun
Chen, Xiang
Peng, Defei
Zhang, Xiangyan
Zhou, Jianda
author_facet Liu, Can
Xie, Huiqing
Yu, Jingang
Chen, Xiaoqing
Tang, Shijie
Sun, Lichun
Chen, Xiang
Peng, Defei
Zhang, Xiangyan
Zhou, Jianda
author_sort Liu, Can
collection PubMed
description BACKGROUND: Nowadays, the combination of microRNA (miR) is attracting increased attention in clinical cancer trials. However, the clinical use of miR is highly limited because of certain properties such as instability, low-specificity distribution, and metabolic toxicity. METHODS: In order to improve the anti-tumor efficacy and reduce the side effects of miR in treating melanoma, a combination of graphene oxide (GO), chitosan (CS), and a cellular penetrating peptide, MPG, was prepared with solid dispersion method in this research. The research has analyzed the specific components of nano drug-loading complexes GO-CS and GO-CS-MPG through characterization research and confirmed the bio-safety of the carrier material GO-CS-MPG. RESULTS: The GO-CS-MPG-miR33a/miR199a nano drug-loading complex was successfully constructed and its medical effectiveness was verified. Through the subcutaneous tumor implantation experiment, an evident effect of the drug-loading complex in inhibiting melanoma cells was proven. CONCLUSION: Results suggest that GO-CS-MPG may have potential applications in melanoma therapy.
format Online
Article
Text
id pubmed-6157538
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-61575382018-10-01 A targeted therapy for melanoma by graphene oxide composite with microRNA carrier Liu, Can Xie, Huiqing Yu, Jingang Chen, Xiaoqing Tang, Shijie Sun, Lichun Chen, Xiang Peng, Defei Zhang, Xiangyan Zhou, Jianda Drug Des Devel Ther Original Research BACKGROUND: Nowadays, the combination of microRNA (miR) is attracting increased attention in clinical cancer trials. However, the clinical use of miR is highly limited because of certain properties such as instability, low-specificity distribution, and metabolic toxicity. METHODS: In order to improve the anti-tumor efficacy and reduce the side effects of miR in treating melanoma, a combination of graphene oxide (GO), chitosan (CS), and a cellular penetrating peptide, MPG, was prepared with solid dispersion method in this research. The research has analyzed the specific components of nano drug-loading complexes GO-CS and GO-CS-MPG through characterization research and confirmed the bio-safety of the carrier material GO-CS-MPG. RESULTS: The GO-CS-MPG-miR33a/miR199a nano drug-loading complex was successfully constructed and its medical effectiveness was verified. Through the subcutaneous tumor implantation experiment, an evident effect of the drug-loading complex in inhibiting melanoma cells was proven. CONCLUSION: Results suggest that GO-CS-MPG may have potential applications in melanoma therapy. Dove Medical Press 2018-09-21 /pmc/articles/PMC6157538/ /pubmed/30275686 http://dx.doi.org/10.2147/DDDT.S160088 Text en © 2018 Liu et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Liu, Can
Xie, Huiqing
Yu, Jingang
Chen, Xiaoqing
Tang, Shijie
Sun, Lichun
Chen, Xiang
Peng, Defei
Zhang, Xiangyan
Zhou, Jianda
A targeted therapy for melanoma by graphene oxide composite with microRNA carrier
title A targeted therapy for melanoma by graphene oxide composite with microRNA carrier
title_full A targeted therapy for melanoma by graphene oxide composite with microRNA carrier
title_fullStr A targeted therapy for melanoma by graphene oxide composite with microRNA carrier
title_full_unstemmed A targeted therapy for melanoma by graphene oxide composite with microRNA carrier
title_short A targeted therapy for melanoma by graphene oxide composite with microRNA carrier
title_sort targeted therapy for melanoma by graphene oxide composite with microrna carrier
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6157538/
https://www.ncbi.nlm.nih.gov/pubmed/30275686
http://dx.doi.org/10.2147/DDDT.S160088
work_keys_str_mv AT liucan atargetedtherapyformelanomabygrapheneoxidecompositewithmicrornacarrier
AT xiehuiqing atargetedtherapyformelanomabygrapheneoxidecompositewithmicrornacarrier
AT yujingang atargetedtherapyformelanomabygrapheneoxidecompositewithmicrornacarrier
AT chenxiaoqing atargetedtherapyformelanomabygrapheneoxidecompositewithmicrornacarrier
AT tangshijie atargetedtherapyformelanomabygrapheneoxidecompositewithmicrornacarrier
AT sunlichun atargetedtherapyformelanomabygrapheneoxidecompositewithmicrornacarrier
AT chenxiang atargetedtherapyformelanomabygrapheneoxidecompositewithmicrornacarrier
AT pengdefei atargetedtherapyformelanomabygrapheneoxidecompositewithmicrornacarrier
AT zhangxiangyan atargetedtherapyformelanomabygrapheneoxidecompositewithmicrornacarrier
AT zhoujianda atargetedtherapyformelanomabygrapheneoxidecompositewithmicrornacarrier
AT liucan targetedtherapyformelanomabygrapheneoxidecompositewithmicrornacarrier
AT xiehuiqing targetedtherapyformelanomabygrapheneoxidecompositewithmicrornacarrier
AT yujingang targetedtherapyformelanomabygrapheneoxidecompositewithmicrornacarrier
AT chenxiaoqing targetedtherapyformelanomabygrapheneoxidecompositewithmicrornacarrier
AT tangshijie targetedtherapyformelanomabygrapheneoxidecompositewithmicrornacarrier
AT sunlichun targetedtherapyformelanomabygrapheneoxidecompositewithmicrornacarrier
AT chenxiang targetedtherapyformelanomabygrapheneoxidecompositewithmicrornacarrier
AT pengdefei targetedtherapyformelanomabygrapheneoxidecompositewithmicrornacarrier
AT zhangxiangyan targetedtherapyformelanomabygrapheneoxidecompositewithmicrornacarrier
AT zhoujianda targetedtherapyformelanomabygrapheneoxidecompositewithmicrornacarrier